The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
This report authored by Karine Cohen-Solal, PhD, provides a five-month snapshot of the continuous learning collaborative in relapsed or refractory in chronic leukocytic lymphoma and small lymphocytic lymphoma, a joint initiative between SOHO and the Medical Learning Institute.
Live session held on March 18, 2026, from 2:30 – 3 pm CT with speaker Jeffrey Matous presenting on “Managing access to novel agents in the community setting.”
The European Commission (EC) has approved nivolumab (Opdivo®) in combination with brentuximab vedotin for the treatment of adult and pediatric patients with relapsed or refractory classical Hodgkin Lymphoma (cHL). This indication applies to children ages 5 years and older, adolescents, and adults up to 30 years of age who have received one prior line of therapy.
The EBMT analysis was led by first author Anna Ossami Saidy of the Department of Hematology and Cell Therapy at Helios Klinikum Berlin-Buch in Germany.
Beyond this new indication, the drug is already approved in Brazil and the European Union for relapsed or refractory diffuse large B-cell lymphoma, according to the press release by Knight Therapeutics.
To access the SOHO Career Center click the following link.
